METiS TechBio debuts on Hong Kong stock market as its CEO compares the drug design start-up to SpaceX for the pharmaceutical industry
Its stocks first traded at HK$28.68, significantly higher than its offering price of HK$10.50 each.
METiS TechBio’s shares drew strong demand from both retail and institutional investors, as buyers from the mainland and overseas snapped up AI-related stocks in Hong Kong amid a wave of Chinese hi-tech companies rushing to list on the city’s stock exchange. Mike Leung Kit-man, director at Wocom Securities, said, “Several AI-related IPOs have seen their share prices multiply since listing.”
Source: News - South China Morning Post
